Stock Price
103.76
Daily Change
1.65%
Yearly
51.43%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,004.00 -27.00 -0.89% -21.75%
AbbVie 115.28 -1.61 -1.38% 10.80%
Adamas Pharmaceuticals 8.22 0.06 0.74% 91.16%
Aerie Pharmaceuticals 10.10 0.53 5.54% -18.48%
ALKERMES 21.92 -0.48 -2.14% 18.74%
Amgen 198.88 -4.59 -2.26% -11.64%
Antares Pharma 3.23 -0.01 -0.31% 2.87%
AstraZeneca 8,343.00 67.00 0.81% 5.12%
Bristol-Myers Squibb 53.63 -1.01 -1.85% -14.07%
Cara Therapeutics 13.18 0.60 4.77% -10.28%
Coherus Biosciences 18.57 0.37 2.03% -0.59%
Endo International Ordinary Shares 5.60 -0.24 -4.11% 9.38%
Flexion Therapeutics 9.12 -0.02 -0.22% -17.76%
Horizon Pharma 103.76 1.68 1.65% 51.43%
Jazz Pharmaceuticals 119.87 -2.54 -2.08% -16.25%
Eli Lilly 248.04 -6.79 -2.66% 70.40%
Merck & Co 74.91 0.02 0.03% -8.14%
Novartis 74.00 0.56 0.76% -9.67%
Prestige Brands 55.95 0.03 0.05% 55.55%
Pacira 52.62 1.51 2.95% -12.94%
Pfizer 53.73 1.33 2.54% 36.34%
Perrigo 36.71 -0.77 -2.05% -24.23%
Revance Therapeutics 13.68 1.22 9.79% -43.05%
Supernus Pharmaceuticals 29.97 -0.48 -1.58% 36.35%
Teva Pharmaceutical Industries 8.25 -0.34 -3.96% -12.33%
Bausch Health Companies Inc 30.32 -1.47 -4.62% 25.91%
Xeris Pharmaceuticals Inc 2.09 0.05 2.45% -50.36%
Zoetis 222.04 -1.51 -0.68% 37.61%

Indexes Price Day Year
US2000 2199 -43.07 -1.92% 19.76%
NASDAQ 15538 -245.14 -1.55% 25.76%

Horizon Pharma
Horizon Therapeutics plc is a biotechnology company that is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare, autoimmune and serious inflammatory diseases. The Company's portfolio is composed of approximately 12 medicines in the areas of rare diseases, gout, ophthalmology and inflammation. The Company has two reportable segments: the orphan and the inflammation segment. The orphan segment includes the medicines TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, UPLIZNA and also the Company’s research and development (R&D) programs. TEPEZZA is a monoclonal antibody and a targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R). KRYSTEXXA is an infused medicine for uncontrolled gout. The Company's other orphan segment medicines, RAVICTI, PROCYSBI and ACTIMMUNE, treats serious chronic diseases. The inflammation segment includes PENNSAID 2%, DUEXIS, RAYOS and VIMOVO medicines.